Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:08 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 2,447 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Colon/Rectal Cancer Rectal Cancer Clear all

Conditions: Stomach Cancer, Colorectal Cancer, Appendiceal Cancer, Ovarian Cancer, Uterine Cancer, Cervical Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Interventions: HIPEC, Mitomycin c, CDDP 50, CDDP 75, Doxorubicin; Device · Drug
Lead sponsor: Holy Name Medical Center, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Teaneck, New Jersey

Conditions: Pain, Cancer, Colonic Diseases
Interventions: GIC-1001; Drug
Lead sponsor: gicare Pharma Inc.; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 308 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 11
States / cities: Scottsdale, Arizona • Anaheim, California • Chula Vista, California + 8 more

Conditions: Colorectal Cancer, Colon Cancer
Interventions: gemcitabine, capecitabine; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Colorectal Cancer
Interventions: curcumin, rutin, quercetin, sulindac; Dietary Supplement · Drug
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2006
U.S. locations: 1
States / cities: New York, New York

Conditions: Colorectal Cancer, Constipation, Impaction, and Bowel Obstruction, Extrahepatic Bile Duct Cancer, Gastric Cancer, Gastrointestinal Stromal Tumor, Nausea and Vomiting, Ovarian Cancer, Pancreatic Cancer, Peritoneal Cavity Cancer, Small Intestine Cancer
Interventions: octreotide acetate; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2002
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Colorectal Carcinoma
Interventions: Biospecimen Collection, Survey Administration; Procedure · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 45 Years and older · Female only
Enrollment: 146 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis, Asthma, Atopic Dermatitis Eczema, Beta Thalassemia, Bipolar Disorder, Breast Cancer, Celiac Disease, Cervical Cancer, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Kidney Diseases, Chronic Obstructive Pulmonary Disease, Colon Cancer, Colorectal Cancer, Crohn's Disease, Cystic Fibrosis, Depression, Diabetes Mellitus, Duchenne Muscular Dystrophy, Endometriosis, Epilepsy, Facioscapulohumeral Muscular Dystrophy, G6PD Deficiency, General Anxiety Disorder, Hepatitis B, Hereditary Hemorrhagic Telangiectasia, HIV/AIDS, Human Papilloma Virus, Huntington's Disease, Idiopathic Thrombocytopenic Purpura, Insomnia, Kidney Cancer, Leukemia, Lung Cancer, Lupus Nephritis, Lymphoma, Melanoma, Multiple Myeloma, Multiple Sclerosis, Myositis, Myotonic Dystrophy, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Polycystic Kidney Diseases, Prostate Cancer, Psoriasis, Psoriatic Arthritis, Rosacea, Scleroderma, Sickle Cell Anemia, Sickle Cell Trait, Sjogren's Syndrome, Skin Cancer, Spinal Muscular Atrophy, Systemic Lupus Erythematosus, Thrombotic Thrombocytopenic Purpura, Trisomy 21, Ulcerative Colitis
Interventions: Not listed
Lead sponsor: Sanguine Biosciences; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 17,667 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Colorectal Cancer Metastatic
Interventions: Sorafenib Plus Capecitabine (SorCape); Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Metastatic Colorectal Cancer
Interventions: Signatera ctDNA assay, pre-specified sequence of FDA-approved drugs and drug combinations; Device · Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 99 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Colorectal Cancer
Interventions: O6-benzylguanine, carmustine; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Colorectal Cancer, Metastatic Colorectal Cancer
Interventions: Tovecimig, Irinotecan, Leucovorin, 5-Fluorouracil (5-FU); Biological · Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Colorectal Cancer
Interventions: CRC mHealth, Control; Behavioral
Lead sponsor: ISA Associates, Inc.; Other
Eligibility: 45 Years to 75 Years · Male only
Enrollment: 128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Alexandria, Virginia

Conditions: Non-small Cell Lung Carcinoma (NSCLC), Melanoma, Bladder Cancer, Colorectal Cancer, Gastric Cancer, Ovarian Cancer
Interventions: CM-24 (MK-6018), Pembrolizumab (MK-3475); Biological
Lead sponsor: Famewave Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: Los Angeles, California • New Haven, Connecticut

Conditions: Cancer, Solid Tumor, Colorectal Cancer, Pancreas Cancer, Non Small Cell Lung Cancer, Head and Neck Cancer, Gynecologic Cancer, Skin Cancer, Kidney Cancer
Interventions: DK210 (EGFR), Radiation therapy, Immune checkpoint blockers, Chemotherapy; Biological · Radiation · Drug
Lead sponsor: DEKA Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 7
States / cities: Duarte, California • Manhasset, New York • Oklahoma City, Oklahoma + 3 more

Conditions: Rectal Cancer, Cancer of the Rectum, Colorectal Cancer
Interventions: 5-Fluorouracil, Bevacizumab, Radiation Therapy, Oxaliplatin, Leucovorin; Drug · Procedure
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 14
States / cities: Anniston, Alabama • Jonesboro, Arkansas • Fort Myers, Florida + 11 more

Conditions: Prostate Cancer, Colorectal Cancer, Breast Cancer, Cervical Cancer, Lung Cancer
Interventions: Navigation Services, Cancer education; Behavioral
Lead sponsor: University of Utah; Other
Eligibility: Not listed
Enrollment: 1,800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2010
U.S. locations: 2
States / cities: Great Falls, Montana • Salt Lake City, Utah

Conditions: Metastatic Colorectal Cancer, Hepatocellular Carcinoma
Interventions: Enfortumab Vedotin; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Advanced Solid Tumors, EGFR Positive Non-small Cell Lung Cancer, Colorectal Carcinoma, Recurrent Ovarian Carcinoma, BRAF-Mutated Melanoma
Interventions: TP-0903; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 16
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Denver, Colorado + 12 more

Conditions: Colorectal Cancer
Interventions: panitumumab, erlotinib hydrochloride, irinotecan hydrochloride; Biological · Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 10
States / cities: Arlington Heights, Illinois • Chicago, Illinois • Joliet, Illinois + 6 more

Conditions: Colorectal Cancer
Interventions: Imprime PGG + cetuximab, Cetuximab; Biological · Drug
Lead sponsor: HiberCell, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 44
States / cities: Florence, Alabama • Bentonville, Arkansas • Anaheim, California + 38 more

Conditions: Neoplasms
Interventions: Encorafenib, Cetuximab, Oxaliplatin, Irinotecan, Leucovorin, 5-FU, Capecitabine, Bevacizumab; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 16 Years and older
Enrollment: 841 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 63
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 38 more

Conditions: Microsatellite Stable (MSS) Colorectal Cancer (CRC), Metastatic Colorectal Cancer (CRC), Colorectal Cancer Stage IV
Interventions: Pre-Treatment Biopsy, On-Treatment Biopsy, Tiragolumab, Atezolizumab, Bevacizumab; Procedure · Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Colorectal Cancer
Interventions: Capecitabine, Irinotecan; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 17
States / cities: Birmingham, Alabama • Loma Linda, California • Norwich, Connecticut + 12 more

Conditions: Solid Tumors, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Colon Cancer, Rectal Cancer, Neoplasms, Endometrial Cancer, Soft Tissue Sarcoma, Triple Negative Breast Cancer, Pancreas Cancer, Pancreatic Cancer
Interventions: LY2880070, Gemcitabine; Drug
Lead sponsor: Esperas Pharma Inc.; Other
Eligibility: 18 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 2
States / cities: Boston, Massachusetts • Detroit, Michigan

Search by objective public record fields.

Trial of Cytoreductive Surgery and HIPEC in Patients With Primary and Secondary Peritoneal Cancers

A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy

Capecitabine and Gemcitabine in Patients With Metastatic Colorectal Cancer

Sulindac and Plant Compounds in Preventing Colon Cancer

Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery

Blood Test (Guardant Shield™) for Screening of Colorectal Cancer in Underserved Patients

At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions

Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer

A Phase II Randomized Therapeutic Optimization Trial for Subjects With Refractory Metastatic Colorectal Cancer Using ctDNA: Rapid 1 Trial

Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer

Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer

A Smartphone-Based Intervention to Improve Colorectal Cancer Screening in African American Men

Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer

Reducing Cancer Disparities for American Indians in the Rural Intermountain West

Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC

First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors

Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer

Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal Cancer

Capecitabine and Irinotecan in Treating Patients With Locally Advanced, Recurrent, or Metastatic Colorectal Cancer

A Study of LY2880070 in Participants With Advanced or Metastatic Cancer